DiabetOmics
Non-invasive assessment and management of personalized health and diabetes risk
About DiabetOmics
Diabetomics, Inc. is a global medical diagnostics company that specializes in developing innovative, non-invasive tests for early detection of various health conditions. The company is particularly focused on diabetes and maternal health. Diabetomics offers the first and only point-of-care saliva tests for diabetes, which means these tests can be done quickly and easily at the location where the patient is receiving care, without the need for a lab. They also provide early detection tests for preeclampsia (a pregnancy complication) and gestational diabetes, as well as for type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA).
The company operates in the medical diagnostics market, serving healthcare providers, clinics, and potentially individual consumers who need quick and reliable testing solutions. Diabetomics' business model revolves around selling these diagnostic tests to healthcare facilities and directly to consumers. They make money by manufacturing and distributing these tests, leveraging their proprietary technology to offer unique products that are not available from other companies.
In response to the COVID-19 pandemic, Diabetomics has adapted its oral fluid rapid test technology to develop a home-use SARS-CoV-2 antibody test, which can help individuals determine if they have been exposed to the virus.
Diabetomics is ISO 13485:2016 and I.S. EN ISO 13485:2016 certified, which means they meet international standards for quality management systems in the medical device industry. This certification assures clients and partners of the reliability and quality of their products.
Source: Dealroom company dataAt a glance
- Founded
- 2008
- Headquarters
- Hillsboro, United States
- Sector
- Health Tech & Medtech
News
Open roles
DiabetOmics in the Hillsboro ecosystem
The DiabetOmics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- RPRogue Venture Partners
Series B and later1 investor entered at this stage
Ventureast
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about DiabetOmics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See DiabetOmics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


